Sugi Predict

Sugi Predict / Targets / HDAC1

HDAC1

Histone deacetylase 1 · Q13547 · HDAC1 on Sugi Atlas →

946,566 patent compounds predicted against HDAC1, 550,935 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20170 SCHEMBL20170 1.00 20/20
SCHEMBL30213 SCHEMBL30213 1.00 20/20
SCHEMBL30261 SCHEMBL30261 0.95 20/20
SCHEMBL28361 SCHEMBL28361 0.73 20/20
SCHEMBL28362 SCHEMBL28362 0.73 20/20
SCHEMBL19485 SCHEMBL19485 0.72 20/20
SCHEMBL28253 SCHEMBL28253 0.71 20/20
SCHEMBL30024 SCHEMBL30024 0.71 20/20
SCHEMBL30421 SCHEMBL30421 0.71 20/20
SCHEMBL19361 SCHEMBL19361 0.70 20/20
SCHEMBL19362 SCHEMBL19362 0.70 20/20
SCHEMBL28328 SCHEMBL28328 0.66 20/20
SCHEMBL28329 SCHEMBL28329 0.66 20/20
SCHEMBL28330 SCHEMBL28330 0.66 20/20
SCHEMBL29695 SCHEMBL29695 0.66 20/20
SCHEMBL30199 SCHEMBL30199 0.66 20/20
SCHEMBL29911 SCHEMBL29911 0.60 20/20
SCHEMBL29912 SCHEMBL29912 0.60 20/20
SCHEMBL29913 SCHEMBL29913 0.60 20/20
SCHEMBL29914 SCHEMBL29914 0.60 20/20

Clinical trials — most relevant to HDAC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy PHASE2UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma PHASE2RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas PHASE2ACTIVE_NOT_RECRUITING
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma PHASE1COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Imaging Histone Deacetylase in the Heart nanRECRUITING
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer nanWITHDRAWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HDAC1 binder may also engage these)

ProteinNameSimilarity
Q5RAG0 — 1.000 Q5RAG0 →
Q32PJ8 — 1.000 Q32PJ8 →
O09106 — 1.000 O09106 →
P56517 — 1.000 P56517 →
P56519 — 1.000 P56519 →
Q91695 — 1.000 Q91695 →
Q4QQW4 — 1.000 Q4QQW4 →
P56518 — 0.999 P56518 →
Q7Y0Y6 — 0.998 Q7Y0Y6 →
Q9FML2 — 0.998 Q9FML2 →
HDAC2 Histone deacetylase 2 0.997 landscape →
O42227 — 0.997 O42227 →
Q6YV04 — 0.997 Q6YV04 →
P70288 — 0.995 P70288 →
O17695 — 0.995 O17695 →
O22446 — 0.995 O22446 →
P56521 — 0.992 P56521 →
P56523 — 0.992 P56523 →
Q28DV3 — 0.992 Q28DV3 →
Q94517 — 0.992 Q94517 →
Q8H0W2 — 0.991 Q8H0W2 →
O13298 — 0.991 O13298 →
P56520 — 0.991 P56520 →
Q7Y0Y8 — 0.990 Q7Y0Y8 →
HDAC3 Histone deacetylase 3 0.990 landscape →
P32561 — 0.990 P32561 →
Q803C3 — 0.989 Q803C3 →
O59702 — 0.989 O59702 →
Q09440 — 0.988 Q09440 →
Q4SFA0 — 0.987 Q4SFA0 →